Lorlatinib and brain side effects in ALK-positive lung cancer
Part of Brain & nervous system, Cancer clinical trials.
This study looks at how often lorlatinib, a targeted therapy for ALK-positive lung cancer, causes side effects in the brain or nervous system. Researchers hope to find risk factors so doctors can better monitor and manage these effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that is advanced (stage IIIb or beyond) or has spread or come back.
- Your cancer is ALK-positive, which means your tumor has a specific genetic change that lorlatinib targets.
- You are 18 years or older.
- You are taking or will start lorlatinib as your treatment.
- You are willing to have your health data collected and to answer questions about your experience.
- You do not have severe infections like active hepatitis B or C, or HIV, or other serious uncontrolled health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
This trial tests whether it is better to delay brain radiation or give it right away in people with ALK-positive lung cancer that has spread to the brain and is causing few or no symptoms. If you are starting alectinib, you may be able to join and help find the best timing for radiation.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study tests an oral drug called lorlatinib in people with ROS1-positive lung cancer that has spread to the brain. The drug targets the ROS1 mutation and aims to shrink brain tumors and improve outcomes.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
Hear when a new ALK trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.